VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH ALL 2021 | Upcoming trial updates in ALL

David Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, shares upcoming promising clinical trials in the acute lymphoblastic leukemia (ALL) space. The use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, is being evaluated in a randomized trial, and results are awaited with interest. Clinical trials comparing ponatinib and imatinib in Philadelphia chromosome-positive (Ph+) ALL will determine whether ponatinib is a superior treatment agent for Ph+ ALL. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter